{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:47:53Z","timestamp":1772797673623,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T00:00:00Z","timestamp":1249516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00702-009-0275-0","type":"journal-article","created":{"date-parts":[[2009,8,5]],"date-time":"2009-08-05T04:45:26Z","timestamp":1249447526000},"page":"1253-1256","source":"Crossref","is-referenced-by-count":20,"title":["Peripheral COMT inhibition prevents levodopa associated homocysteine increase"],"prefix":"10.1007","volume":"116","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,6]]},"reference":[{"issue":"Suppl 1","key":"275_CR1","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1038\/sj.cdd.4401451","volume":"11","author":"RC Austin","year":"2004","unstructured":"Austin RC, Lentz SR, Werstuck GH (2004) Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11(Suppl 1):S56\u2013S64","journal-title":"Cell Death Differ"},{"key":"275_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jnnp.58.3.293","volume":"58","author":"Y Ben Shlomo","year":"1995","unstructured":"Ben Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293\u2013299","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"275_CR3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/archinte.159.1.38","volume":"159","author":"ML Bots","year":"1999","unstructured":"Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, Koudstaal PJ, Grobbee DE (1999) Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 159:38\u201344","journal-title":"Arch Intern Med"},{"key":"275_CR4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(99)00641-8","volume":"353","author":"BA Faucheux","year":"1999","unstructured":"Faucheux BA, Bonnet AM, Agid Y, Hirsch EC (1999) Blood vessels change in the mesencephalon of patients with Parkinson\u2019s disease. Lancet 353:981\u2013982","journal-title":"Lancet"},{"key":"275_CR5","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1212\/WNL.44.10.1865","volume":"44","author":"JM Gorell","year":"1994","unstructured":"Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson\u2019s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44:1865\u20131868","journal-title":"Neurology"},{"key":"275_CR6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.WNF.0000236763.16032.60","volume":"29","author":"S Hassin-Baer","year":"2006","unstructured":"Hassin-Baer S, Cohen O, Vakil E, Sela BA, Nitsan Z, Schwartz R, Chapman J, Tanne D (2006) Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 29:305\u2013311","journal-title":"Clin Neuropharmacol"},{"key":"275_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","volume":"20","author":"P Lamberti","year":"2005","unstructured":"Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de MM, Livrea P (2005) Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson\u2019s disease patients. Mov Disord 20:69\u201372","journal-title":"Mov Disord"},{"key":"275_CR8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","volume":"26","author":"ES Lee","year":"2005","unstructured":"Lee ES, Chen H, Soliman KF, Charlton CG (2005) Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26:361\u2013371","journal-title":"Neurotoxicology"},{"key":"275_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","volume":"20","author":"JW Miller","year":"1997","unstructured":"Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41\u20130960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55\u201366","journal-title":"Clin Neuropharmacol"},{"key":"275_CR10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1586\/14737175.8.6.957","volume":"8","author":"T M\u00fcller","year":"2008","unstructured":"M\u00fcller T (2008) Role of homocysteine in the treatment of Parkinson\u2019s disease. Expert Rev Neurother 8:957\u2013967","journal-title":"Expert Rev Neurother"},{"key":"275_CR11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","volume":"62","author":"T M\u00fcller","year":"2006","unstructured":"M\u00fcller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson\u2019s disease patients. Eur J Clin Pharmacol 62:447\u2013450","journal-title":"Eur J Clin Pharmacol"},{"key":"275_CR12","doi-asserted-by":"crossref","unstructured":"M\u00fcller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson\u2019s disease. Mov Disord [Epub ahead of print]","DOI":"10.1002\/mds.22607"},{"key":"275_CR13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","volume":"61","author":"T M\u00fcller","year":"2004","unstructured":"M\u00fcller T, Renger K, Kuhn W (2004) Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61:657\u2013660","journal-title":"Arch Neurol"},{"key":"275_CR14","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00702-007-0773-x","volume":"114","author":"T M\u00fcller","year":"2007","unstructured":"M\u00fcller T, Ander L, Kolf K, Woitalla D, Muhlack S (2007) Comparison of 200\u00a0mg retarded release levodopa\/carbidopa\u2014with 150\u00a0mg levodopa\/carbidopa\/entacapone application: pharmacokinetics and efficacy in patients with Parkinson\u2019s disease. J Neural Transm 114:1457\u20131462","journal-title":"J Neural Transm"},{"key":"275_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","volume":"207","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sasaki K, Nakashima K (2003) Hypertrophy of IMC of carotid artery in Parkinson\u2019s disease is associated with l-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 207:19\u201323","journal-title":"J Neurol Sci"},{"key":"275_CR16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","volume":"112","author":"E Nissinen","year":"2005","unstructured":"Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, Rauhala P (2005) The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112:1213\u20131221","journal-title":"J Neural Transm"},{"key":"275_CR17","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","volume":"61","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB Jr, Bottiglieri T, Diaz-Arrastia R (2004) Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 61:865\u2013868","journal-title":"Arch Neurol"},{"key":"275_CR18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.parkreldis.2005.10.002","volume":"12","author":"PE O\u2019Suilleabhain","year":"2006","unstructured":"O\u2019Suilleabhain PE, Oberle R, Bartis C, Dewey RB Jr, Bottiglieri T, az-Arrastia R (2006) Clinical course in Parkinson\u2019s disease with elevated homocysteine. Parkinsonism Relat Disord 12:103\u2013107","journal-title":"Parkinsonism Relat Disord"},{"key":"275_CR19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1179\/016164106X110445","volume":"28","author":"F Ozer","year":"2006","unstructured":"Ozer F, Meral H, Hanoglu L, Aydemir T, Yilsen M, Cetin S, Ozturk O, Seval H, Koldas M (2006) Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 28:853\u2013858","journal-title":"Neurol Res"},{"key":"275_CR20","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","volume":"66","author":"RB Postuma","year":"2006","unstructured":"Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66:1941\u20131943","journal-title":"Neurology"},{"key":"275_CR21","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/mds.21085","volume":"21","author":"C Reitz","year":"2006","unstructured":"Reitz C, Trenkwalder C, Kretzschmar K, Roesler A, v Eckardstein A, Berger K (2006) Relation of cerebral small-vessel disease and brain atrophy to mild parkinsonism in the elderly. Mov Disord 21:1914\u20131919","journal-title":"Mov Disord"},{"key":"275_CR22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","volume":"11","author":"P Valkovic","year":"2005","unstructured":"Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P (2005) Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients. Parkinsonism Relat Disord 11:253\u2013256","journal-title":"Parkinsonism Relat Disord"},{"key":"275_CR23","first-page":"5","volume":"1","author":"D Woitalla","year":"2004","unstructured":"Woitalla D, Kuhn W, M\u00fcller T (2004) MTHFR C677T polymorphism, folic acid and hyperhomocysteinemia in levodopa treated patients with Parkinson\u2019s disease. J Neural Transm Suppl 1:5\u201320","journal-title":"J Neural Transm Suppl"},{"key":"275_CR24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","volume":"29","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA (2006) The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 29:106\u2013111","journal-title":"Clin Neuropharmacol"},{"key":"275_CR25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","volume":"11","author":"S Zoccolella","year":"2005","unstructured":"Zoccolella S, Lamberti P, Armenise E, de MM, Lamberti SV, Mastronardi R, Fraddosio A, Iliceto G, Livrea P (2005a) Plasma homocysteine levels in Parkinson\u2019s disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 11:131\u2013133","journal-title":"Parkinsonism Relat Disord"},{"key":"275_CR26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1515\/CCLM.2005.193","volume":"43","author":"S Zoccolella","year":"2005","unstructured":"Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, de MM, Livrea P (2005b) Plasma homocysteine levels in l-dopa-treated Parkinson\u2019s disease patients with cognitive dysfunctions. Clin Chem Lab Med 43:1107\u20131110","journal-title":"Clin Chem Lab Med"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0275-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0275-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0275-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:25:15Z","timestamp":1559089515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0275-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,6]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["275"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0275-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,6]]}}}